Curated News
By: NewsRamp Editorial Staff
October 15, 2026
Oncotelic Unveils PDAOAI Platform and HCC Research at Drug Discovery 2026
TLDR
- Oncotelic's PDAOAI platform indexes 29 million PubMed abstracts, giving researchers a competitive edge in biomedical literature analysis.
- PDAOAI searches and organizes 29 million PubMed abstracts, then connects selected projects to funding and development support through BIO REBOOT.
- Oncotelic's PDAOAI platform and BIO REBOOT funding support may accelerate development of therapies that improve patient outcomes and save lives.
- At Drug Discovery 2026, Oncotelic presented a four-gene HCC signature linked to survival in an exploratory analysis and a Japanese cohort.
Impact - Why it Matters
This news matters because it showcases how artificial intelligence can be harnessed to navigate the overwhelming volume of biomedical literature—exemplified by the 29 million PubMed abstracts indexed by PDAOAI—to uncover actionable insights for drug development. By demonstrating a four-gene signature associated with survival in hepatocellular carcinoma, Oncotelic illustrates the potential of AI-driven discovery to identify novel biomarkers and therapeutic targets. As the pharmaceutical industry increasingly turns to AI to streamline research and reduce costs, platforms like PDAOAI could become essential tools for scientists and companies aiming to accelerate the translation of data into treatments. Moreover, the integration of BIO REBOOT to support selected projects suggests a growing ecosystem where computational discoveries are linked with funding and development, potentially bringing new therapies to patients faster.
Summary
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing a development strategy that integrates biomedical literature analysis with therapeutic development. At Drug Discovery 2026 in Burlingame, California, Scott Myers, Product Manager, and Saran Saund, Chief Business Officer, showcased the company's PDAOAI platform. Myers presented “The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development” on October 7, detailing how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. On October 8, Saund followed with an HCC case study, describing how disease-specific literature analysis led to a four-gene mTOR-related signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort.
The PDAOAI platform is designed to help researchers organize scientific evidence and develop hypotheses for further investigation. BIO REBOOT connects the platform’s research capabilities with potential funding and development support for selected projects, creating a pathway from discovery to development. The presentations highlighted the platform's ability to aggregate and analyze vast amounts of biomedical literature, potentially accelerating the identification of promising therapeutic targets.
For investors and researchers, Oncotelic’s approach represents a convergence of AI-driven knowledge discovery and practical drug development. The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC. The event was covered by InvestorWire, a specialized communications platform, and IBN, which deliver wire-grade press release syndication and corporate communications solutions. Read More>>
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic Unveils PDAOAI Platform and HCC Research at Drug Discovery 2026
